Inflammatory bowel diseases · 2026
Soluble transferrin receptor as a reliable inflammation-independent marker of iron deficiency in Crohn's disease and ulcerative colitis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Portela Francisco, Ministro Paula, de Sousa Helena Tavares, Roseira Joana, Fernandes Samuel, Crespo Ricardo, Domingues Beatriz, Santiago Mafalda, Melo-Miranda Rita, Dias Sandra, Dias Cláudia Camila, Magro Fernando
Аннотация
BACKGROUND: Iron deficiency is a common complication in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). However, standard iron markers are influenced by inflammation, complicating the diagnosis of true iron deficiency. Soluble transferrin receptor (sTfR) has been proposed as a more reliable, inflammation-independent marker of iron demand. This study aimed to assess the utility of sTfR in identifying iron deficiency without anemia (IDWA).
METHODS: The ID_IBD study was a multicenter, cross-sectional study. Iron status was classified using two approaches: the ECCO consensus definition, focusing on ferritin thresholds adjusted for inflammatory markers (C-reactive protein [CRP] and fecal calprotectin [FCAL]), and a stricter definition that adds transferrin saturation to the ECCO criteria. sTfR levels were compared across groups, and ROC curve analysis was used to identify optimal diagnostic cut-offs.
RESULTS: This analysis included 411 IBD patients (130 UC, 281 CD) and 178 controls. sTfR showed no correlation with CRP or FCAL. In UC, patients with IDWA had significantly higher sTfR levels (median 1.20 mg/L, IQR 1.02-1.42) compared to non-IDWA patients (median 1.05 mg/L, IQR 0.92-1.22; P = .013). Anemic UC patients also showed elevated sTfR levels (median 1.27 mg/L, IQR 1.14-1.59) compared to non-IDWA individuals (P < .001). In CD, sTfR did not significantly differ between IDWA and non-IDWA patients but was significantly higher in anemic patients (P = .003).
CONCLUSIONS: sTfR appears to be an inflammation-independent marker of iron status in IBD. It showed greater potential for identifying IDWA in UC, while in CD it mainly reflected increased iron demand in anemia. Overall, sTfR may be useful as a complementary parameter to conventional iron markers. Further longitudinal studies are warranted to validate these findings and assess their clinical utility in IBD.
METHODS: The ID_IBD study was a multicenter, cross-sectional study. Iron status was classified using two approaches: the ECCO consensus definition, focusing on ferritin thresholds adjusted for inflammatory markers (C-reactive protein [CRP] and fecal calprotectin [FCAL]), and a stricter definition that adds transferrin saturation to the ECCO criteria. sTfR levels were compared across groups, and ROC curve analysis was used to identify optimal diagnostic cut-offs.
RESULTS: This analysis included 411 IBD patients (130 UC, 281 CD) and 178 controls. sTfR showed no correlation with CRP or FCAL. In UC, patients with IDWA had significantly higher sTfR levels (median 1.20 mg/L, IQR 1.02-1.42) compared to non-IDWA patients (median 1.05 mg/L, IQR 0.92-1.22; P = .013). Anemic UC patients also showed elevated sTfR levels (median 1.27 mg/L, IQR 1.14-1.59) compared to non-IDWA individuals (P < .001). In CD, sTfR did not significantly differ between IDWA and non-IDWA patients but was significantly higher in anemic patients (P = .003).
CONCLUSIONS: sTfR appears to be an inflammation-independent marker of iron status in IBD. It showed greater potential for identifying IDWA in UC, while in CD it mainly reflected increased iron demand in anemia. Overall, sTfR may be useful as a complementary parameter to conventional iron markers. Further longitudinal studies are warranted to validate these findings and assess their clinical utility in IBD.